Sionna Therapeutics, Inc.(SION)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
SION Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Sionna Therapeutics, Inc. (SION), a Healthcare sector company. SION is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Sionna Therapeutics, Inc. reports net income of $-26.8M, free cash flow of $-21.8M. Top institutional holders of SION by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., TPG GP A,, ORBIMED ADVISORS, based on the most recent SEC filings. SION trades on the Nasdaq exchange and files with the SEC under CIK 2036042. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SION daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sionna Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-26.8M
Free Cash Flow
Q1 2026
$-21.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
Operating Income
EPS (Diluted)
Total Assets
Op. Cash Flow
| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Net Income | $-61.7M | — |
| Operating Income | $-70.6M | — |
| EPS (Diluted) | $-15.99 | — |
| Total Assets | $185.8M | — |
| Operating Cash Flow | $-52.8M | — |
AI Insight: SION Financial Trends
Sionna's cash burn accelerated sharply in Q1 2026, with operating losses widening 25% quarter-over-quarter to -$30M, compressing equity to $288M.
• Operating losses widened from -$20M in Q1 2025 to -$30M in Q1 2026, a 50% increase year-over-year.
• Equity eroded steadily from $352M in Q1 2025 to $288M in Q1 2026, a $64M decline over four quarters.
• Operating cash outflow jumped to -$22M in Q1 2026, the largest single-quarter burn in the five-quarter window.
⚠ At Q1 2026's -$22M quarterly operating cash burn, remaining equity of $288M implies roughly 13 quarters of runway.
⚠ Q1 2026 loss acceleration (-$27M net vs. -$20M prior quarter) may signal rising R&D spend — watch for pipeline milestones justifying the step-up.
AI Insight: SION Ratio Trends
Return metrics are deteriorating sharply, with ROIC worsening from -22.4% in Q1 2025 to -41.1% in Q1 2026 — a pre-revenue biotech burning cash faster each quarter.
• ROIC deteriorated continuously from -22.4% in Q1 2025 to -41.1% in Q1 2026, a 18.7pp decline over five quarters.
• ROA worsened from -17.8% in Q1 2025 to -35.1% in Q1 2026, signaling accelerating asset consumption relative to returns.
• ROE fell from -18.7% in Q1 2025 to -37.2% in Q1 2026, reflecting shareholder equity eroding at an increasing pace.
⚠ OpMargin, NPM, and D/E are entirely absent across all periods — insufficient data to assess cost structure or leverage trajectory.
⚠ TTM ROIC of -34.3% vs. Q1 2026 quarterly ROIC of -41.1% suggests burn is intensifying beyond the trailing-year average.
Get alerted when SION's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Sionna Therapeutics, Inc. including:
Top Institutional Holders of SION
RA CAPITAL MANAGEMENT, L.P.
$397.1M9,905,045 shTPG GP A, LLC
$260.4M6,494,962 shORBIMED ADVISORS LLC
$141.5M3,530,702 shVIKING GLOBAL INVESTORS LP
$128.1M3,195,181 shAtlas Venture Life Science Advisors, LLC
$120.1M2,995,602 shEnavate Sciences GP, LLC
$99.3M2,478,030 shJENNISON ASSOCIATES LLC
$58.2M1,451,220 shBlackRock, Inc.
$52.0M1,295,867 shCITADEL ADVISORS LLC
$46.8M1,166,931 shVANGUARD CAPITAL MANAGEMENT LLC
$41.3M1,029,497 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $397.1M | 9,905,045 |
| TPG GP A, LLC | $260.4M | 6,494,962 |
| ORBIMED ADVISORS LLC | $141.5M | 3,530,702 |
| VIKING GLOBAL INVESTORS LP | $128.1M | 3,195,181 |
| Atlas Venture Life Science Advisors, LLC | $120.1M | 2,995,602 |
| Enavate Sciences GP, LLC | $99.3M | 2,478,030 |
| JENNISON ASSOCIATES LLC | $58.2M | 1,451,220 |
| BlackRock, Inc. | $52.0M | 1,295,867 |
| CITADEL ADVISORS LLC | $46.8M | 1,166,931 |
| VANGUARD CAPITAL MANAGEMENT LLC | $41.3M | 1,029,497 |
More Healthcare Companies
View all Healthcare →Put SION on your watchlist
Track score changes the day Sionna Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SION a good stock to buy?
13F Pro's AI-powered analysis of Sionna Therapeutics, Inc. (SION) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SION are available on the SION stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own SION?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SION. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sionna Therapeutics, Inc.'s investment landscape.